BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schotten C, Bechmann LP, Manka P, Theysohn J, Dechêne A, El Fouly A, Barbato F, Neumann U, Radünz S, Sydor S, Heider D, Venerito M, Canbay A, Gerken G, Herrmann K, Wedemeyer H, Best J. NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. Liver Cancer 2019;8:491-504. [PMID: 31799206 DOI: 10.1159/000501484] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Liang L, Sun LY, Diao YK, Yang T. Comparison of Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma. Liver Cancer 2020;9:361-2. [PMID: 32647637 DOI: 10.1159/000506353] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Schotten C, Wedemeyer H, Best J. Reply to the Letter to the Editor: "Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma". Liver Cancer 2020;9:363-4. [PMID: 32647638 DOI: 10.1159/000506947] [Reference Citation Analysis]